›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:Oncomine Focus Assay
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Thermo Fisher ScientificType:
Laboratory Developed Test
Related tests:
Oncomine Focus Assay is a targeted, multi-biomarker assay that enables detection of hotspots, SNVs, indels, CNVs, and gene fusions from DNA and RNA in a single workflow. This comprehensive assay design is further enhanced with workflow automation, delivering insights quickly and helping accelerate your research towards that next companion diagnostic or therapy in the future. It simultaneous detects hundreds of variants across 52 genes relevant to solid tumors. It enables detection of NTRK1, NTRK2, and NTRK3 gene fusions
Cancer:
Solid Tumor
Gene:
AKT1 (V-akt murine thymoma viral oncogene homolog 1), ALK (Anaplastic lymphoma kinase), AR (Androgen receptor), BRAF (B-raf proto-oncogene), CDK4 (Cyclin-dependent kinase 4), CTNNB1 (Catenin (cadherin-associated protein), beta 1)
See More ...
AKT1 (V-akt murine thymoma viral oncogene homolog 1), ALK (Anaplastic lymphoma kinase), AR (Androgen receptor), BRAF (B-raf proto-oncogene), CDK4 (Cyclin-dependent kinase 4), CTNNB1 (Catenin (cadherin-associated protein), beta 1), DDR2 (Discoidin domain receptor 2), EGFR (Epidermal growth factor receptor), ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3), ERBB4 (erb-b2 receptor tyrosine kinase 4), FGFR2 (Fibroblast growth factor receptor 2), FGFR3 (Fibroblast growth factor receptor 3), GNA11 (G Protein Subunit Alpha 11), GNAQ (G Protein Subunit Alpha Q), HER-2 (Human epidermal growth factor receptor 2), HRAS (Harvey rat sarcoma viral oncogene homolog), IDH1 (Isocitrate dehydrogenase (NADP(+)) 1), IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2), JAK1 (Janus Kinase 1), JAK2 (Janus kinase 2), JAK3 (Janus Kinase 3), KIT (KIT proto-oncogene, receptor tyrosine kinase), KRAS (KRAS proto-oncogene GTPase), MAP2K1 (Mitogen-activated protein kinase kinase 1), MAP2K2 (Mitogen-activated protein kinase kinase 2), MET (MET proto-oncogene, receptor tyrosine kinase), NRAS (Neuroblastoma RAS viral oncogene homolog), NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1), NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2), NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3), PDGFRA (Platelet Derived Growth Factor Receptor Alpha), PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase), RET (Ret Proto-Oncogene), ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS), SMO (Smoothened Frizzled Class Receptor), mTOR (Mechanistic target of rapamycin kinase)
Method:
Next-Generation Sequencing (NGS)
